| Revenue growth | Q2 revenue +24.7% to ~₹373 Cr; constant-currency ~16%. |
|---|---|
| Margins | EBITDA margin 16% to 17.6% in Q2; gross margin down 170 bps H1. |
| Demand visibility | Growth across all categories and regions; Europe 23%, India 15%. |
| Management confidence | Upbeat, 'record quarter' framing, though margin pressure acknowledged. |
Growth
Constant-currency Q2 growth ~16% vs reported 24.7%, currency aided. H1 EBITDA +43.4%; gross margin down 170 bps.
Outlook
EBITDA margin +150–200 bps yearly; ~20% by FY29. Constant-currency revenue growth mid-to-high teens; capex ~₹70 Cr FY27–28.
Risks
Gross margin down 170 bps on traded mix and input costs. Reported H1 PAT +7.5%; ETR 32–35% for two to three years.
Earnings Call Transcript filed with NSE, NSE: SMT. Summary written with AI assistance from the document.
Sahajanand Medical Technologies Ltd: key numbers
- Share price
- ₹487.75
- Market cap
- ₹4,958 Cr
- Revenue (annual)
- ₹1,210 Cr
- Net profit (annual)
- ₹65.28 Cr
- Promoter holding
- 36.20%
- FII holding
- 35.09%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Sahajanand Medical Technologies Ltd
All →Sahajanand Medical Technologies Board Meeting Outcome
Sahajanand Medical Technologies' board appointed M/s Amit Jaste & Associates as Secretarial Auditor for FY 2026-27 to FY 2030-31. The appointment is subject to shareholder approval.
- Execution
- FY 2026-27 to FY 2030-31, five consecutive financial years, subject to shareholder approval
Sahajanand Medical Technologies Acquisition Worth ₹7.33 Cr
Sahajanand Medical's Irish subsidiary approved up to USD 7,80,000 investment in SNP Medical Corp. This lifts its stake to 17.19%, a related-party deal at arm's length.
- Value
- ₹7.33 Cr
- Execution
- Tentatively completed by 31 March 2027
Sahajanand Medical Technologies Investor Presentation: Key Takeaways
Q2 FY27 record: revenue ₹3,734mn (+24.7%), EBITDA ₹656mn (17.6% margin), PAT ₹265mn (+26.6%). H1 revenue ₹7,251mn (+24.9%). Growth led by Other and Shockwave-type SH products.
Sahajanand Medical Technologies Q2 FY27 Results: Net Profit ₹26.5 Cr, Up 26.8% YoY
Sahajanand Medical Technologies Ltd reported revenue from operations of ₹373.4 Cr (+24.7% YoY) and net profit of ₹26.5 Cr (+26.8% YoY) for Q2 FY27.
- Key figure
- Net profit ₹26.5 Cr · +26.8% YoY
Sahajanand Medical Technologies Legal & Regulatory
Sahajanand Medical Technologies received a GST DRC-01D recovery notice from Jharkhand tax authorities. The demand totals Rs. 34.29 lakh, which the company is contesting before appellate authorities.
- Value
- ₹0.34 Cr
Sahajanand Medical Technologies Credit Rating
CRISIL has upgraded Sahajanand Medical Technologies' long-term bank facility rating to CRISIL A-/Stable from BBB+/Stable. The upgrade reflects improved business risk, growing scale, and sustained profitability across its global stent manufacturing operations.
- Value
- ₹300.0 Cr